Total
0
Shares
Claritas Pharmaceuticals (TSX:KLY) forms Nitric Oxide Scientific Advisory Board
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Claritas Pharmaceuticals ( CLAS) is expanding its R-107 development program to include the treatment of COVID-19 related sepsis
  • Sepsis is the leading cause of death in COVID-19 patients
  • Data suggests that R-107 significantly reduced mortality in an aggressive and clinically predictive animal model of sepsis
  • Claritas Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company
  • Claritas Pharmaceuticals ( CLAS) opened trading at C$0.04 per share

Claritas Pharmaceuticals ( CLAS) is expanding its R-107 development program to include the treatment of COVID-19 related sepsis.

Sepsis is the leading cause of death in COVID-19 patients.

Most COVID-19 infections cause mild to moderate illness with respiratory and flu-like symptoms, including fever, chills, cough and sore throat. However, in a significant number of patients, the disease progresses from these initial mild symptoms to more serious and potentially fatal viral sepsis.

In COVID-19 viral sepsis, the body has a dysregulated immune response to the coronavirus, which causes severe oxidant stress and life-threatening dysfunction in organs including the lungs, brain, kidneys, heart, and liver. COVID-19 viral sepsis is the leading cause of death among COVID-19 infected patients, with a mortality rate in the range of 30% - 40%.

“The data we are announcing today demonstrate that R-107 significantly reduced mortality in an aggressive and clinically predictive animal model of sepsis. The importance of these data cannot be overstated,” said Robert Farrell, Claritas’ President and CEO.

“While bacterial sepsis may be treated with antibiotics, this is not the case with COVID-19 viral sepsis. Approved therapies, such as remdesivir, dexamethasone and bamlanivimab, are helpful for patients with mild illness but are not particularly effective in COVID-19 patients who have developed sepsis. For COVID-19 patients who have developed sepsis, there are few available therapies beyond supportive care.”

Mr. Farrell went on to state that,

“Our data unequivocally demonstrate that R-107 treatment reduced mortality in a controlled study in a large animal model of sepsis. We are aware of no other drug that is marketed or in development that has achieved superior results in this animal model of the disease.”

Claritas Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for patients with significant unmet medical needs.

Claritas Pharmaceuticals ( CLAS) opened trading at C$0.04 per share.

More From The Market Herald
Assure (TSXV:IOM) approved to list on NASDAQ Capital Market

" Assure (TSXV:IOM) approved to list on NASDAQ Capital Market

Assure Holdings (IOM) has been approved to list its shares on the NASDAQ Capital Market.
Levitee Labs - CEO, Pouya Farmand. - The Market Herald Canada

" Levitee Labs (CSE:LVT) announces DTC eligibility

Common shares of Levitee Labs (LVT) are now eligible to be electronically cleared and settled through the DTC.
Transcontinental - President and CEO, François Olivier. - The Market Herald Canada

" Transcontinental’s (TSX:TCL.A) CEO François Olivier to retire

Transcontinental (TCL.A) CEO François Olivier will retire on December 9, 2021, after 28 years with the company.
Fortress Technologies (TSXV:FORT) announces leadership transition and asset purchase agreement

" Fortress Technologies (TSXV:FORT) announces leadership transition and asset purchase agreement

Fortress Technologies (FORT) has appointed Antonin “AJ” Scalia as CEO and Thomas “Drew” Armstrong as president and COO.